Targovax ASA announced that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022. Most recently, he served as Managing Director and Head of Europe at Locust Walk. Before Locust Walk, he was Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall and Head of Europe Search and Evaluation for oncology at Bristol-Myers Squibb.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
9.42 NOK | +13.77% | +318.67% | +30.83% |
25/04 | Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
17/04 | Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.83% | 64.96L | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-0.47% | 2.18TCr | |
-9.23% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- TRVX Stock
- News Circio Holding ASA
- Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022